Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares from a Blood Sample
Machine Learning Approaches to Predict Lupus Disease Activity from Gene Expression Data
The integration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant challenge because of the high degree of heterogeneity among patients...
Doctors and patients monitor Lupus with mobile app
CLICK TO VIEW ORIGINAL ARTICLE > by Josh Mandell A Charlottesville company is helping to lead a global scientific effort to better understand and treat lupus, an autoimmune disease...
Trial of LuPRO mobile app predicts Lupus flares
CLICK TO VIEW ORIGINAL ARTICLE > BY KATIE O'CONNOR, Richmond Times-Dispatch In 50 years, only one treatment was approved by the U.S. Food and Drug Administration to treat lupus, an autoimmune...